Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced positive topline results from two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback